The distal hinge of the reactive site loop and its proximity - A target to modulate plasminogen activator inhibitor-1 activity

被引:37
作者
Bijnens, AP
Gils, A
Stassen, JM
Komissarov, AA
Knockaert, I
Brouwers, E
Shore, JD
Declerck, PJ
机构
[1] Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium
[2] Boehringer Ingelheim Pharma KG, Cardiovasc Pharmacol, D-88397 Biberach, Germany
[3] Henry Ford Hlth Ctr, Div Biochem Res, Detroit, MI 48202 USA
关键词
D O I
10.1074/jbc.M103077200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The serpin plasminogen activator inhibitor type 1 (PAI-1) plays a regulatory role in various physiological processes (e.g. fibrinolysis and pericellular proteolysis) and forms a potential target for therapeutic interventions. In this study we identified the epitopes of three PAI-1 inhibitory monoclonal antibodies (MA-44E4, MA-42A2F6, and MA-56A7C10). Differential cross-reactivities of these monoclonals with PAI-1 from different species and sequence alignments between these PAI-1s, combined with the three-dimensional structure, revealed several charged residues as possible candidates to contribute to the respective epitopes. The production, characterization, and subsequent evaluation of a variety of alanine mutants using surface plasmon resonance revealed that the residues His(185), Arg(186), and Arg(187) formed the major sites of interaction for MA-44E4. In contrast, the epitopes of MA-42A2F6 and MA-56A7C10 were found to be conformational. The epitope of MA-42A2F6 comprises residues Lys(243) and Glu(350), whereas the epitope of MA-56A7C10 comprises residues Glu(242), Lys(243), Glu(244), Glu(350) Asp(355) and Arg(356). The participation of Glu(350), Asp(355), and Arg(356) provides a molecular explanation for the differential exposure of this epitope in the different conformations of PAI-1 and for the effect of these antibodies on the kinetics of the formation of the initial PAI-1-proteinase complexes. The localization of the epitopes of MA-44E4, MA42A2F6, and MA-56A7C10 elucidates two previously unidentified molecular mechanisms to modulate PAI-1 activity and opens new perspectives for the rational development of PAI-1 neutralizing compounds.
引用
收藏
页码:44912 / 44918
页数:7
相关论文
共 57 条
  • [51] VAGUE IJ, 1987, THROMB HAEMOSTASIS, V58, P1096
  • [52] VERHEIJEN JH, 1984, THROMB HAEMOSTASIS, V51, P392
  • [53] Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1
    Vleugels, N
    Leys, J
    Knockaert, I
    Declerck, PJ
    [J]. THROMBOSIS AND HAEMOSTASIS, 2000, 84 (05) : 871 - 875
  • [54] Evaluation of the mechanism of inactivation of plasminogen activator inhibitor-1 by monoclonal antibodies using a stable variant
    Vleugels, N
    Gils, A
    Mannaerts, S
    Knockaert, I
    Declerck, PJ
    [J]. FIBRINOLYSIS & PROTEOLYSIS, 1998, 12 (05): : 277 - 282
  • [55] WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652
  • [56] Wiman B, 1999, SCAND J CLIN LAB INV, V59, P23
  • [57] Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1 - Implications for antibody-mediated PAI-1-neutralization and vitronectin-binding
    Wind, T
    Jensen, MA
    Andreasen, PA
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 2001, 268 (04): : 1095 - 1106